Coherus Oncology (CHRS) EPS (Weighted Average and Diluted) (2015 - 2026)

Coherus Oncology has disclosed EPS (Weighted Average and Diluted) across 12 years of filings, most recently posting -$0.27 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.27, up 44.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.54 (up 236.28% YoY), and the FY2025 annual result was -$1.56, down 724.0% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.27 for Q1 2026 at Coherus Oncology, up from -$0.38 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.57 in Q2 2025 to a low of -$1.24 in Q1 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.44 (2024), against an average of -$0.3.
• Peak annual rise in EPS (Weighted Average and Diluted) reached 2436.36% in 2025, while the deepest fall reached 322.22% in 2025.
• Coherus Oncology's EPS (Weighted Average and Diluted) stood at -$0.76 in 2022, then climbed by 2.63% to -$0.74 in 2023, then soared by 40.54% to -$0.44 in 2024, then rose by 13.64% to -$0.38 in 2025, then grew by 28.95% to -$0.27 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.27 (Q1 2026), -$0.38 (Q4 2025), and -$0.38 (Q3 2025), per Business Quant data.